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4 (6) 
2 (3) 
3 (4) 
24 (36) 
20 (29) 
3 (4) 
1 (1) 
2 (3) 
9 (12) 
 
Conclusions: This system based on artificial intelligence automatically 
enables the classification of tumor size in BC. Among the data mining 
algorithms, the J48 algorithm had the highest percentage of correctly 
classified cases and allows changes (i.e.: guideline updates). This tool 
would save time in the data collection, prevent errors, and improve 
tumor classification as well as the quality of the therapeutic decision.  
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Purpose/Objective: Breast conserving surgery and post-operative 
whole breast radiotherapy (RT) have proved to reduce local 
recurrence and improve survival of early stage breast cancer patients. 
On the other hand, it has been demonstrated that long-term survivors 
have a significantly higher risk of lung complications and cardiac 
death as a consequence of heart and lung irradiation during tangential 
breast RT. Respiratory gating RT provides a chance to reduce heart 
and lung doses. This study evaluates the cardiopulmonary dose sparing 
of a prospective-gating RT for left breast cancer using a four-
dimensional computed tomography (4DCT) technique.  
Materials and Methods: Patients with early left breast cancer, 
referred for adjuvant radiotherapy to our Institution,were enrolled in 
this study. For each patient, two simulation CT-scans were acquired: 
the first during free breathing and the second on prospective gating 
during deep inspiration breath-hold. The scans were monitored by the 
Varian RPMTM respiratory gating system. Whole heart and pericardium 
was contoured starting superiorly just below the left pulmonary 
artery. For each patient, two treatment plans, based on the two CT 
studies, were performed with conformal tangential fields. Maximum 
lung distance (MLD) was measured on beams eye view. Mean heart 
dose (MHD), heart V25, ipsilateral lung V20 and V30 were evaluated. 
Dose-volume histograms were calculated and compared by the paired 
sample T-test. 
Results:  
 From January to November 2012, 71 patients were enrolled. Median 
age was 50 years (range 30-76),the mean breathing period was 4.3s 
(range 2-12.9), and the mean 4DCT scanning time was 12.2 s (range 5-
19). Overall patients’ compliance was good The average MHD was 3.2 
Gy (range 0.90-8.70) in the 4D plans and 1.8 Gy (range 0.50-4.70) in 
the 3D plans (p<0.0001). The mean heart V25 was 2.25% (range 0-
12.60) and 0.14% (range 0-3.40) for 3D and 4D plans, respectively 
(p<0.0001). The average MLD was 2.17 cm (range 0.97-3.74) on 3D 
plans and 2.43 cm (range 1.25-4.0) on the 4D plans (p<0.0001). The 
mean lung V20 and V30 were 11.28% (range 1.70-27.50) and 9.37% 
(range 1.10-24.80) for 3D plans, and 9.25 % (range3.50-20.60) and 
7.89% (range 2.40-30) for 4D plans (p<0.0001 and p=0.0035, 
respectively).  
Conclusions: Prospective gating tangential RT to left breast allows the 
delivery of a significantly lower dose to heart. The MLD was 
significantly higher on 4D plans, but the ipsilateral lung received an 
overall smaller dose of RT, as demonstrated by the significantly lower 
V20 and V30.  
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Purpose/Objective: The aim of this prospective study is to evaluate 
feasibility, early and late skin toxicity in women treated with 
hypofractionated whole breast irradiation schedule for breast cancer. 
Materials and Methods: Between 2/ 2008 and 4/ 2011, 40 women 
with invasive early breast cancer were treated with conservative 
surgery followed by sentinel-node biopsy in 47.5% and axillary 
dissection in 40%. No axillary node surgery was performed in 12.5% of 
cases. The median age was 72 years (range 56-85). Hystology was as 
follows: infiltrating ductal carcinoma 30/40 pts , infiltrating lobular 
carcinoma 6/40 pts, CDI and CLI 1/40 pt, others 3/40 pts. Stage was 
as follows: pT1 in 33 pts (82.5%), pT2 in 7 pts (17.5%). The axillary 
lymph nodes were negative in 77.5% and positive (pN1a) in 12.5% . 
Thirty-five pts received adjuvant hormone therapy and 3 pts received 
adjuvant systemic therapy respectively. Radiation therapy was 
delivered by means of two opposed tangential fields. Using the 
original planning computer tomography scans the entire breast and 
OARs were delineated. The DVH histograms were accepted just if PTV 
was included in ICRU constraints. All pts were treated with 6-15 MV x-
rays. Median whole-breast irradiation dose prescribed was 40.05Gy 
(range: 40 - 42.5 Gy) administered in 15-16 fractions of 2.5-2.67Gy (5 
fractions/week). Boost irradiation to the tumor bed with the doses of 
2 to 3 Gy/fraction was performed in 4 cases. No attempt was made to 
treat the axilla or the supraclavicular or internal mammary nodes. 
Results: All pts completed the schedule. The median follow-up was 18 
months (range 16-54 months). All pts were routinely evaluated to 
register acute side effects and late skin toxicity according to RTOG 
criteria. At the end of treatment 50% presented grade 0 acute skin 
toxicity, 35% had grade 1 and 15% had grade 2. At 6 months there 
were 30% cases of grade 1 skin toxicity and 7.5% of grade 2. At 12 
months 45% and 5 % of pts presented with clinical grade 1 and grade 2 
fibrosis respectively and 5% presented hyperpigmentation. At 24 
months, with 21 patients evaluated, just 1 pt showed grade 2 late 
fibrosis. The remaining pts were free of side effects. No pts 
experienced local relapse, nor distant metastasis. 
Conclusions: Our data showed a good feasibility of the 
hypofractionated schedule in terms of acute and late skin toxicity. 
The hypofractionated schedule shortens the overall treatment time 
and represents a biologically acceptable alternative to the traditional 
6 weeks regime. 
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Purpose/Objective: Functional imaging is known as accurate tool for 
evaluation of chemotherapy (CHT) efficacy in patients (pts) with 
breast cancer (BC). We determine the group of patients with excellent 
functional response to neoadjuvant chemotherapy as a potential 
candidates for breast irradiation instead of mastectomy. 
Materials and Methods: 50 primary pts with advanced BC (T3-4, N1-2) 
were included in this study. Breast scintigraphy (BS) was done before 
the start of CHT and after 2-6 cycles of treatment with taxane-
doxorubicin based regimes ± trastuzumab. BS was performed 10-15 
min after i/v injection of 740 MBq of 99mTc-MIBI. Qualitative and 
semiquantitative scores were used to qualify dynamic of tracer uptake 
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(TU). CHT efficacy were estimated as follows: progression (grade I) – 
increase of area and/or intensity of TU; stabilization (II) – unchanged 
image of BC; partial effect (III) – intermediate (30-70%) decrease in 
intensity and area of TU in BC; prominent efficacy (IV) – only small 
foci of low residual TU in BC; complete resolution (V) – TU in BC on 
the level of background. 
Results: BS detected complete resolution of TU in primary tumor in 10 
(20%) of 50 treated pts, in additional 12 (24%) cases efficacy of CHT 
was prominent, 15 (30%) women had scintigraphic sings of 
stabilization or progression of BC. 
Number of CHT cycles significantly influence character of BS changes. 
After 2 cycles of TAC ± trastuzumab 2 of 10 patients demonstrated 
sings of grade IV, one – of grade III tumor response and other 7- 
stabilization or progression of BC. 
After 3 cycles 7 (44%) of 16 women had good (grade IV-V) efficacy of 
CHT, in other 9 (56%) cases scintigraphic response was moderate or 
poor (grade I-III). 
After 4-6 CHT cycles TU uptake in primary tumor disappeared (V) or 
become markedly reduced (IV) in 13 (54%) of 24 patients. In 6 (25%) 
women BS data reflect non-significant efficacy of CHT. 
Conclusions: BS performed after 4-6 cycles of TAC ± trastuzumab CHT 
indicate that more than a half (56%) of women with advanced BC 
become the candidates for breast irradiation instead of mastectomy.  
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Purpose/Objective: 1) To compare mean heart and left anterior 
descending coronary artery (LAD) doses from left breast radiotherapy 
(RT) delivered using different fractionation schedules and techniques 
(free breathing (FB) versus activated breathing controlled deep 
inspiratory breath-hold (ABC_DIBH).  
2) To define a useable surrogate variable for mean heart and LAD dose 
in order to facilitate plan comparison. 
Materials and Methods: Sixteen patients whose hearts were within 
tangents based on radiotherapy planning CT scans in FB were 
subsequently scanned in ABC_DIBH. Heart, LAD, whole breast/chest 
wall and partial breast clinical target volumes were outlined 
retrospectively. Plans were prepared for each patient and for both 
techniques according to ICRU 62 criteria. DVH data for three different 
fractionation schedules (50Gy/25#, 40Gy/15# and 27Gy/5#) were used 
to determine heart and LAD *NTDmean and NTDmean per fraction as well 
as the volume of heart receiving 25% of the prescribed dose (heart 
V25%) (*NTDmean is a biologically weighted mean of total dose to tissue 
normalised to 2Gy fractions using a standard linear quadratic model). 
In addition the maximum heart depth (MHD) was measured. The 
correlation between heart NTDmean/NTDmean per fraction and both 
heart V25% and MHD was assessed.  
Results: For 27Gy/5#, 40Gy/15# and 50Gy/25# plans respectively, 
mean heart NTDmean for FB plans was 2.7, 3.1 and 3.5Gy (p<0.001) and 
for ABC 0.7, 0.9 and 1.1Gy (p<0.001). Mean LAD NTDmean for FB plans 
was 19.4, 20.1 and 22.6Gy (p<0.001) and for ABC 5.7, 6.4, 7.4Gy 
(p<0.001). Mean heart NTDmean per fraction for FB plans was 0.55, 0.20 
and 0.14Gy (p<0.001) and for ABC 0.14, 0.06 and 0.04Gy (p<0.001). 
Mean LAD NTDmean per fraction for FB plans was 3.88, 1.35 and 0.90Gy 
(p<0.001) and for ABC 1.15, 0.43and 0.30Gy (p<0.001). Linear 
correlation r2 values of0.98 and 0.72 were obtained for the correlation 
between heart NTDmean/heartNTDmean per fraction and heart V25% and 
MHD respectively. 
Conclusions: Heart and LAD NTDmean decrease with the increasingly 
hypofractionated schedules assessed here. In contrast, heart and LAD 
NTDmean per fraction increase with increasingly hypofractionated 
schedules. Heart V25% is a useful and easily derived surrogate for heart 
NTDmean/NTDmean per fraction. 
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Purpose/Objective: To report the 4-year results of accelerated 
partial breast irradiation (APBI) by means of three-dimensional 
conformal radiotherapy (3D-CRT) following breast-conserving surgery 
(BCS) for early-stage breast cancer. 
Materials and Methods: Between 2006 and 2010, in 44 cases of low-
risk, pT1-2 (≤30 mm) pN0 M0 breast cancer, postoperative APBI was 
given by means of 3D-CRT using 3 to 5 non-coplanar fields. The total 
dose of APBI was 36.9 Gy (9 x 4.1 Gy) using a twice-a-day 
fractionation over 5 consecutive days. Four-year survival results, early 
and late toxicities, and cosmetic results were analyzed. 
Results: At a mean follow-up of 47.5 months neither loco-regional nor 
distant failure was observed. No patient died of breast cancer, but 
two of them died of internal disease. The 4-year probability of overall 
survival was 93.3%. Grade 2 or worse acute side-effect was not 
observed. Data on late toxicities and cosmetic results were available 
in 43 cases (97.7%). Grade 1, 2, and 3 fibrosis occurred in 22 (51.2%), 
7 (16.3%), and 1 (2.3%) patients, respectively. Only 4 patients (9.3%) 
developed slight (grade 1) skin hyperpigmentation. No patient 
developed grade 2-4 late skin side effect. Asymptomatic fat necrosis 
was detected in 8 cases (18.6%) on follow-up mammography. 
Excellent, good, fair, and poor cosmetic outcome was reported in 12 
(27.9%), 23 (53.5%), 8 (18.6%), and 0 (0%) patients, respectively. 
Conclusions: 3D-CRT is a feasible technique for the delivery of APBI 
following conservative surgery for the treatment of low-risk, early-
stage invasive breast carcinoma. Four-year results are promising, 
early- and mid-term radiation side effects are rare, and cosmetic 
results are excellent. 
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Purpose/Objective: Different breath movement management 
techniques have been described which effectively spare the heart in 
tangential breast irradiation. The most easy and cheapest way is 
voluntary moderately Deep Inspiration Breath Hold (vmDIBH), but 
reproducibility, and thus actual dose delivery, of this method is 
unclear. The aim of this study is to determine whether the 2D 
measured delivered transit dose is comparable for vmDIBH and free 
breathing (FB) breast irradiations.  
Materials and Methods: Data of 11 patients irradiated during vmDIBH 
and 9 patients irradiated in FB were analyzed. Patients were 
irradiated using a forward IMRT technique to a total dose of 42.7 or 50 
Gy in 16 or 25 fractions,respectively. A Shrinking Action Level (SAL) 
protocol was used for set-up verification using α=10 mm and nmax=3. 
2D transit portal dosimetry was performed for the tangential fields on 
various days, resulting in 386 and 156 measurements for the vmDIBH 
and FB patients, respectively. The delivered transit dose was 
compared to a predicted dose by calculating global gamma values 
with gamma criteria of 3% and 3 mm. The percentage of pixels with an 
absolute gamma value>1 (γ>1) was determined for each measured 
fraction, for both latero-medial and medio-lateral beams. Mean values 
of this parameter were compared between the vmDIBH and FB patient 
groups. Gamma images with more than 5% of the pixels >1 were 
classified as 'failed'. To find an explanation for these failures, these 
gamma images were evaluated visually. If an image showed isolated 
regions of both underdosage and overdosage, gamma and hence dose 
differences were considered to be due to a simple translation 
(residual set-up error or organ motion); if a gamma image showed 
other patterns, dose differences were considered to be due to 
rotation or deformation of the breast.  
Results: The |γ|>1 for all patients was on average 22.0%±10.9% (1 
SD). For the vmDIBH and FB patients, these values were 22.3±11.1% 
and 21.3%±10.5% (1 SD), respectively. No significant difference was 
found (p>0.05). 76% of the gamma images were classified as 'failed', 
77% in vmDIBH patients and 73% in FB patients. In both groups, 24% of 
the 'failures' was attributed to translations. The |γ|>1was 24.4±11.0% 
and 20.2±9.9% (1 SD) for the medio-lateral fields, respectively 
(p>0.05). For the latero-medial fields, these numbers were 22.7±10.8% 
and 24.5± 12.1% (1 SD), respectively (p>0.05) (Figure 1). 
